ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Incidence, prevalence and mortality of Parkinson's disease in Greece.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strengthening Parkinson's disease epidemiology: refining diagnosis and survival metrics.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson’s disease is a progressive neurological condition with significant social burden, expected to rise in the future. Epidemiological research is essential to inform data-driven health policies and unravel new insights into its pathogenesis and potential prevention.
methodsWe used a drug prescription database with extensive population coverage to calculate, nationwide and regional, incidence and prevalence rates of Parkinson’s disease. Additionally, we calculated mortality rates, crude case fatality risk and mortality rate ratios relative to the general population.
resultsThe crude incidence, prevalence and mortality rates were estimated at 48 cases per 100,000 person-years [95% CI 47–50], 400 cases per 100,000 persons [95% CI 396–404] and 71 deaths per 100,000 person-years [95% CI 69–72] respectively. A male predominance was observed across all rates within age-groups. The mortality rate ratios for Parkinson disease patients aged 70–79 and > 80 compared to the general population were estimated at 6.6 [95% CI 6.3–6.9] and 2.0 [95% CI 1.9–2.0] respectively. Incidence and prevalence varied significantly by region with the lowest incidence recorded in Crete at 35 cases per 100,000 person-years [95% CI 30–39] and the highest in Thessaly at 69 cases per 100,000 person-years [95% CI 63–76].
conclusionsOur results provide robust epidemiological evidence to guide the strategic allocation of health system and social resources for Parkinson’s disease in Greece. Additionally, they set the stage for further analytical epidemiological studies to elucidate factors contributing to geographical variations of the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.